ES2149216T3 - Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos. - Google Patents

Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos.

Info

Publication number
ES2149216T3
ES2149216T3 ES93923615T ES93923615T ES2149216T3 ES 2149216 T3 ES2149216 T3 ES 2149216T3 ES 93923615 T ES93923615 T ES 93923615T ES 93923615 T ES93923615 T ES 93923615T ES 2149216 T3 ES2149216 T3 ES 2149216T3
Authority
ES
Spain
Prior art keywords
treatment
disorders
cognoscitive
pct
piperazine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923615T
Other languages
English (en)
Spanish (es)
Inventor
Ian Anthony Cliffe
Allan Fletcher
Alan Chapman White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
John Wyeth and Brother Ltd
Original Assignee
John Wyeth and Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wyeth and Brother Ltd filed Critical John Wyeth and Brother Ltd
Application granted granted Critical
Publication of ES2149216T3 publication Critical patent/ES2149216T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ES93923615T 1992-11-05 1993-10-25 Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos. Expired - Lifetime ES2149216T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929223153A GB9223153D0 (en) 1992-11-05 1992-11-05 Piperazine derivatives

Publications (1)

Publication Number Publication Date
ES2149216T3 true ES2149216T3 (es) 2000-11-01

Family

ID=10724559

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923615T Expired - Lifetime ES2149216T3 (es) 1992-11-05 1993-10-25 Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos.

Country Status (18)

Country Link
US (1) US5827847A (en:Method)
EP (1) EP0877612B1 (en:Method)
JP (1) JP3238153B2 (en:Method)
AT (1) ATE195422T1 (en:Method)
AU (1) AU682155B2 (en:Method)
CA (1) CA2148593C (en:Method)
DE (1) DE69329252T2 (en:Method)
DK (1) DK0877612T3 (en:Method)
ES (1) ES2149216T3 (en:Method)
GB (1) GB9223153D0 (en:Method)
GR (1) GR3034400T3 (en:Method)
HU (1) HUT72049A (en:Method)
LV (1) LV12734B (en:Method)
MX (1) MX9306879A (en:Method)
PT (1) PT877612E (en:Method)
TW (1) TW252043B (en:Method)
WO (1) WO1994009780A1 (en:Method)
ZA (1) ZA937827B (en:Method)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710481A1 (en) * 1994-11-02 1996-05-08 Duphar International Research B.V Use of flesinoxan for cognition enhancement
US6271234B1 (en) * 1997-08-01 2001-08-07 Recordati S.A., Chemical And Pharmaceutical Company 1,4-disubstituted piperazines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2355502A1 (fr) * 1976-06-23 1978-01-20 Roussel Uclaf Application a titre de medicaments d'un derive de la piperazine et de ses sels
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
GB2222768B (en) * 1988-06-17 1992-01-22 Nat Res Dev Analgesic compounds and compositions
GB8909209D0 (en) * 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
US4902687A (en) * 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
HUT54666A (en) * 1989-04-22 1991-03-28 Wyeth John & Brother Ltd Process for producing peperazine derivatives and pharmaceutical compositions containing them
EP0395313B1 (en) * 1989-04-22 1999-12-15 American Home Products Corporation Tertiary alkyl functionalized piperazine derivatives
EP0398413A1 (en) * 1989-05-16 1990-11-22 Duphar International Research B.V "3,4-dehydropiperidine derivatives having psychotropic activity
WO1991011435A2 (en) * 1990-01-11 1991-08-08 The Upjohn Company NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS
GB9022820D0 (en) * 1990-10-19 1990-12-05 Wyeth John & Brother Ltd Piperazine derivatives
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
DE4135551A1 (de) * 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen

Also Published As

Publication number Publication date
ATE195422T1 (de) 2000-09-15
GB9223153D0 (en) 1992-12-16
DE69329252D1 (de) 2000-09-21
DK0877612T3 (da) 2000-10-09
MX9306879A (es) 1995-01-31
DE69329252T2 (de) 2001-03-29
AU5342194A (en) 1994-05-24
AU682155B2 (en) 1997-09-25
TW252043B (en:Method) 1995-07-21
LV12734A (en) 2001-10-20
HU9501290D0 (en) 1995-06-28
JPH08502743A (ja) 1996-03-26
US5827847A (en) 1998-10-27
PT877612E (pt) 2000-11-30
EP0877612B1 (en) 2000-08-16
CA2148593A1 (en) 1994-05-11
JP3238153B2 (ja) 2001-12-10
GR3034400T3 (en) 2000-12-29
EP0877612A1 (en) 1998-11-18
CA2148593C (en) 2005-12-06
LV12734B (en) 2002-01-20
ZA937827B (en) 1995-04-21
WO1994009780A1 (en) 1994-05-11
HUT72049A (en) 1996-03-28

Similar Documents

Publication Publication Date Title
IL123142A0 (en) The use of adamantan-derivatives for the treatment of the inner ear
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ATE120738T1 (de) 2,4-diamino-pyrimidin-3-oxid-derivate und deren verwendung bei der behandlung und zur verhütung von haarfall.
DE69229674D1 (de) 5-ht4 rezeptor antagonisten
ES2134929T3 (es) Derivados de pirrolo-piridina como ligandos para receptores de dopamina.
DK0572635T3 (da) Hidtil ukendte forbindelser med guanidinstruktur og farmaceutisk komposition indeholdende forbindelserne
ES2123756T3 (es) Derivados de piperazina.
NO972938L (no) Farmasöytiske piperazinforbindelser
ES2149216T3 (es) Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos.
ZA941934B (en) Piperazine derivatives
PT1068184E (pt) Derivados n-ariloxietilamina para o tratamento de depressao
HU9502067D0 (en) N-acyl pyrrolidines and drugs for the treatment or prevention of cholecystokinin and gastrin-related disorders
DK0691846T3 (da) Imidazoquinoxalinoner til behandling af sygdomme i centralnervesystemet
GB9304632D0 (en) Amide derivatives
ES2123836T3 (es) Imidazo(1,5-a)quinoleinas para el tratamiento de la ansiedad y trastornos del sueño.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 877612

Country of ref document: ES